The sensitivity of the autoantibody against CCT5 was not significantly different from that of CYFRA 21-1, however, the sensitivity of the autoantibody against CCT5 was significantly higher than that of CEA for identifying stage I NSCLC (P <0.05). The gene discussed is CCT5; the disease is non-small cell lung carcinoma.